Retinoic acid ( DrugBank: Retinoic acid )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
94	原発性硬化性胆管炎	2
231	α1−アンチトリプシン欠乏症	3

94. 原発性硬化性胆管炎

臨床試験数 : 148 / 薬物数 : 118 - (DrugBank : 39) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 141

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03359174 (ClinicalTrials.gov)	May 29, 2018	27/11/2017	An Efficacy Trial of Low Dose All-trans Retinoic Acidin Patients With Primary Sclerosing Cholangitis ...	An Efficacy Trial of Low Dose All-trans Retinoic Acid(ATRA) in Patients With Primary Sclerosing Chol ...	Cholangitis, Sclerosing	Drug: All-trans retinoic acid	Yale University	NULL	Terminated	18 Years	80 Years	All	2	Phase 2	United States
2	NCT01456468 (ClinicalTrials.gov)	October 2011	14/10/2011	Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid(ATRA) for Treatment ...	Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid(ATRA) for Treatment ...	Cholangitis, Sclerosing	Drug: Oral all-trans retinoic acid (ATRA)	Yale University	Mayo Clinic	Completed	18 Years	80 Years	Both	19	Phase 1	United States

First Previous1Next Last

231. α1−アンチトリプシン欠乏症

臨床試験数 : 93 / 薬物数 : 77 - (DrugBank : 8) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 36

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2004-001688-23-GB (EUCTR)	18/02/2008	19/10/2005	A multicentre, double-blind, placebo-controlled randomized trial of the efficacy, safety and tolerab ...	A multicentre, double-blind, placebo-controlled randomized trial of the efficacy, safety and tolerab ...	symptomatic emphysema secondary to alpha-1-antitrypsin deficiency	Product Name: Not applicable Product Code: RO3300074 INN or Proposed INN: None assigned Other descripti ...	F. Hoffmann-La Roche Ltd	NULL	Not Recruiting	Female: yes Male: yes	300	Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Pha ...	Spain;Denmark;United Kingdom
2	EUCTR2004-001688-23-DK (EUCTR)	05/07/2006	30/05/2006	A multicentre, double-blind, placebo-controlled randomized trial of the efficacy, safety and tolerab ...	A multicentre, double-blind, placebo-controlled randomized trial of the efficacy, safety and tolerab ...	symptomatic emphysema secondary to alpha-1-antitrypsin deficiency	Product Name: Not applicable Product Code: RO3300074 INN or Proposed INN: None assigned Other descripti ...	F. Hoffmann-La Roche Ltd	NULL	Not Recruiting	Female: yes Male: yes	300		United Kingdom;Denmark;Spain
3	EUCTR2004-001688-23-ES (EUCTR)	27/10/2004	21/10/2004	A multicentre, double-blind, placebo-controlled randomized trial of the efficacy, safety and tolerab ...	A multicentre, double-blind, placebo-controlled randomized trial of the efficacy, safety and tolerab ...	symptomatic emphysema secondary to alpha-1-antitrypsin deficiency	Product Name: Not applicable Product Code: RO3300074 INN or Proposed INN: None assigned Other descripti ...	F. Hoffmann-La Roche Ltd	NULL	Not Recruiting	Female: yes Male: yes	300	Phase 2	Spain;Denmark;United Kingdom

First Previous1Next Last

先頭へ